Drugs / ION224
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04932512 | Jun 2021 → Jan 2024 | NAFLD1 | Ionis Pharmaceuticals, Inc. | Completed | Met primary |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2024-03-13 | Ionis Pharmaceuticals | Results Ionis announces positive results from Phase 2 study of ION224, an investigational medicine demonstrating clinical efficacy in the treatment of NASH/MASH ionis.com ↗
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced positive results from a Phase 2 study of ION224, an investigational DGAT2 antisense inhibitor in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), previously referred to as nonalcoholic steatohepatitis (NASH). |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2024-03-13 | Ionis Pharmaceuticals | Ionis announces positive results from Phase 2 study of ION224, an investigational medicine demonstrating clinical efficacy in the treatment of NASH/MASH ionis.com ↗ |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ION224 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04932512 ↗ |
| Action | Inhibit | “ION224, a liver-directed antisense inhibitor of diacylglycerol O-acyltransferase 2 (DGAT2)” PMID 40849139 ↗ Aug 2025 |
| Modality | Antisense oligonucleotide | “Antisense oligonucleotide DGAT-2 inhibitor” PMID 40849139 ↗ Aug 2025 |
| Route | Subcutaneous | “subcutaneous injections of ION224 60 mg, 90 mg, or 120 mg, or placebo, once per month” PMID 40849139 ↗ Aug 2025 |
| Target | DGAT2 | “inhibitor of diacylglycerol O-acyltransferase 2 (DGAT2)” PMID 40849139 ↗ Aug 2025 |